Inhibition of fatty acid synthase with FT-4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non-alcoholic fatty liver disease: Results from two early-phase randomized trials February 23, 2021 By Lisa Jarl
Cotadutide (MEDI0382), a dual receptor agonist with balanced glucagon-like peptide-1 and glucagon activity, modulates hepatic glycogen stores October 31, 2019 By Christina Moberg
Gastric bypass promotes more lipid mobilization than a similar weight loss induced by low-calorie diet. October 31, 2019 By Christina Moberg
Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. October 31, 2019 By Christina Moberg
Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. October 31, 2019 By Christina Moberg
Effects of n-6 PUFAs compared with SFAs on liver fat, lipoproteins, and inflammation in abdominal obesity: a randomized controlled trial. October 31, 2019 By Christina Moberg
Overfeeding polyunsaturated and saturated fat causes distinct effects on liver and visceral fat accumulation in humans October 31, 2019 By Christina Moberg
Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: A double-blind, randomized, placebo-controlled study. October 31, 2019 By Christina Moberg
The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients. October 21, 2019 By Christina Moberg
The effect of ticagrelor on growth of small abdominal aortic aneurysms – a randomized controlled trial. October 21, 2019 By Christina Moberg